The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
Abstract
PURPOSE: The epidermal growth factor (EGF) receptor is frequently overexpressed in epithelial tumors. C225 is a human-to-murine chimeric monoclonal antibody that binds to the receptor and inhibits growth of cancer cells expressing the receptor. We evaluated the pharmacokinetics and toxicity of C225 in patients with advanced tumors overexpressing EGF receptors. PATIENTS AND METHODS: We treated 52 patients in three successive phase I clinical trials of C225 as a single dose (n = 13), weekly multiple dose (n = 17), and weekly multiple dose with cisplatin (n = 22). C225 dose levels were 5, 20, 50, and 100 mg/m 2. In the study combining C225 with cisplatin, limited to patients with either head and neck or non–small-cell lung cancer, C225 was further escalated to 200 and 400 mg/m 2. Cisplatin was given at a dose of 60 mg/m 2 once every 4 weeks, and treatment was continued for up to 12 weeks if no disease progression occurred. RESULTS: C225 displayed nonlinear pharmacokinetics, with antibody doses in the range of 200 to 400 mg/m 2 being associated with complete saturation of systemic clearance. C225 clearance did not change with repeated administration or with coadministration of cisplatin. Antibodies against C225 were detected in only one patient, and C225-associated toxicity was minimal. Patients experiencing disease stabilization were seen in all studies. In the study combining C225 and cisplatin, nine (69%) of 13 patients treated with antibody doses ≥ 50 mg/m 2 completed 12 weeks of therapy, and two partial responses were observed. CONCLUSION: C225 has dose-dependent pharmacokinetics, and doses that achieve saturation of systemic clearance are well tolerated. C225 given in combination with cisplatin has biologic activity at pharmacologically relevant doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Carpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
Autocrine growth factors and cancer
Sporn, M. B., & Roberts, A. B. (1985) · Nature · doi:10.1038/313745a0 · Cited by 1,438
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Self-citationRECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS
Carpenter, G. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004313 · Cited by 1,281
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Self-citationGoldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Self-citationPetit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Self-citationRusch, V. W., Baselga, J. M., Cordon‐Cardo, C., Orazem, J. P., Zaman, M., Hoda, S. A., McIntosh, J., Kurie, J. M., & Dmitrovsky, E. (1993) · PubMed · Cited by 482
Self-citationFan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Self-citationGill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Self-citationMasui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., & Mendelsohn, J. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446
Self-citationPietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Self-citationSlamon, D. J. (1998) · Medical Entomology and Zoology · Cited by 347
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 344
Self-citationFan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
Self-citationPeng, D., Fan, Z., Yang, L., DeBlasio, T., Scher, H. I., & Mendelsohn, J. M. (1996) · PubMed · Cited by 280
Self-citationMarco, E. D., Pierce, J. H., Fleming, T. P., Kraus, M. H., Molloy, C. J., Aaronson, S. A., & Fiore, P. P. D. (1989) · PubMed · Cited by 266
The Physiology Of Transforming Growth Factor-α
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60289-4 · Cited by 258
Fan, Z., Masui, H., Altas, I., & Mendelsohn, J. M. (1993) · PubMed · Cited by 245
Self-citationAboud-Pirak, E., Hurwitz, E., Pirak, M., Bellot, F., Schlessinger, J., & Sela, M. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.20.1605 · Cited by 231
Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T. J., Koff, A., & Mendelsohn, J. M. (1996) · PubMed · Cited by 228
Self-citationRodeck, U., Herlyn, M., Herlyn, D., Molthoff, C. F. M., Atkinson, B., Varello, M. A., Steplewski, Z., & Koprowski, H. (1987) · PubMed · Cited by 150
Arteaga, C. L., Winnier, A. R., Poirier, M. C., et al. (1994) · PubMed · Cited by 128
Cohen, D., Simak, R., Fair, W. R., et al. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)32335-2 · Cited by 93
Perez-Soler, R., Donato, N. J., Shin, D. M., Rosenblum, M. G., Zhang, H. Z., Tornos, C. S., Brewer, H., Chan, J. C., Lee, J. S., & Hong, W. K. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.730 · Cited by 70
Khazaeli, M. B. (1989) · Hybridoma · doi:10.1089/hyb.1989.8.231 · Cited by 16
Cited by
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Self-citation
Metadata
- Authors
- Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H., & Mendelsohn, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-14
- Volume
- 18
- Issue
- 4
- Pages
- 904-904
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1939364580
- Cited by
- 741
- References
- 30
- FWCI
- 26.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.